drugset / Trial / NCT00498745

Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

NCT00498745

Phase 1 Completed 36 enrolled Puma Biotechnology, Inc.
RandomizedCrossoverOpen-label

Summary

To evaluate the comparative bioavailability of 2 new tablet formulations of HKI-272 with a reference capsule and an oral solution in healthy subjects.

Timeline

Start
2007-07
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Neratinib Small molecule 240 mg Oral

Indications

No indication recorded.